What You Should Know:
- Tempus and GlaxoSmithKline (GSK) announced an accelerated phase II study evaluating the efficacy and safety of niraparib, an oral, once daily PARP inhibitor, for patients with breast and pancreatic cancers. The study, titled “Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors” (the PAVO study, NCT05169437) is sponsored by Tempus and opened for enrollment on January 7, 2022.
- This trial’s data-driven design and site selection
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Sanofi Taps BrightInsight for Development of Software as a Medical Device
What You Should Know:
- Sanofi, a global biopharmaceutical company focused on human health has inked a strategic partnership with BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solution to bring to market a next-generation digital companion application for one of Sanofi’s products.
- The BrightInsight® Platform has been selected to serve as the underlying infrastructure to accelerate continuous development of one of Sanofi’s
Read More
PostEra Secures $24M, Forms $260M AI Lab Collaboration with Pfizer
What You Should Know:
- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients.
- PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform. True to its collaborative ethos, the company today also announced its
Read More
Verily, Sosei Heptares Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases
What You Should Know:
- Verily and Sosei Heptares announced a new research collaboration combining Verily’s Immune Profiler platform, a next gen immune mapping platform, with Sosei Heptares’ world-leading StaR (stabilized receptor) platform, with the goal of rapidly identifying novel drug candidates across multiple immune-based disorders.
- Together, the collaboration will focus on accelerating the development of new drug candidates against
Read More
Protai Nabs $8M for AI-Powered Drug Discovery Platform
What You Should Know:
- Protai, a Tel Aviv, Israel-based AI-powered drug discovery startup, today announced its emergence from stealth, along with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech.
- Protai empowers drug discovery with proteomics and artificial intelligence to unlock new layers of biological insights and to combat complex diseases.
Proteomics-based Platform for Faster and More Accurate Drug Discovery
Despite the significant
Read More
Illumina and Syapse Partner on Biomarker Testing Research Across Oncology Practices
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced a partnership with Illumina aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community oncology health system setting.
- Together, the two companies will work to better understand biomarker testing patterns among clinicians, which have become foundational in identifying treatment options for cancer patients. The insights gleaned from this
Read More
COVID-19: As Omicron Variant Spreads, Let’s Not Repeat Rookie Mistakes
No one should be surprised there’s another COVID variant on the loose, and yet seemingly, everyone is. The variant, named Omicron (the fifteenth letter in the Greek alphabet), was first reported to the World Health Organisation (WHO) by South Africa on November 24th. Unlike its name would suggest, Omicron is the seventh COVID-19 variant of concern—but a pandemic-fatigued global public could be forgiven for thinking it’s the twentieth.
Governments across the developed world have pushed
Read More
Quidel Corporation Acquires Ortho Clinical Diagnostics for $6B
What You Should Know:
- Quidel Corporation (NASDAQ: QDEL) (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho”) jointly announced that they have entered into a definitive agreement in which Quidel will acquire Ortho.
- The acquisition will create a global leader in diagnostics, bringing together two highly complementary portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing.
Financial Terms of
Read More
Northwell Launches Virtual Clinical Trial to Reduce Cardiovascular Disease in Black Community
What You Should Know:
- The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received a $150k grant from TD Bank, America's Most Convenient Bank, to launch a new research program and the first clinical trial to reduce cardiovascular disease in the Black community and determine the best behavioral interventions to lower Cardiovascular disease (CVD).
Impact of Cardiovascular Disease in Black Community
Cardiovascular disease (CVD) is a major driver
Read More
How 3D Printing is Revolutionizing Orthotics for Patients and Providers
For the 77% of Americans who suffer from foot pain,1 seeking relief has included a litany of options: medications, exercises, insoles and even surgery to name a few. But relief is often hit-or-miss, and insoles that are customized traditionally include a very time-consuming process for patients. They often require lengthy office visits, multiple fit adjustments and even then, not always offering the right fit.
Fortunately, advancements in technology are changing the game. Software,
Read More
